Artal Group
Latest statistics and disclosures from Artal Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are QQQ, WW, BGNE, GS, XLRN, and represent 35.02% of Artal Group's stock portfolio.
- Added to shares of these 10 stocks: QQQ (+$572M), GS (+$136M), MRTX (+$83M), Allovir (+$64M), Ke Hldgs (+$53M), IGMS (+$51M), Iteos Therapeutics (+$27M), Taysha Gene Therapies (+$26M), MS (+$24M), BAC (+$24M).
- Started 27 new stock positions in Kymera Therapeutics, Pmv Pharmaceuticals, CHMA, Taysha Gene Therapies, Pandion Therapeutics, MRTX, MCRB, Iteos Therapeutics, AAPL, BMRN.
- Reduced shares in these 10 stocks: JPM (-$193M), ALXN (-$56M), BPMC (-$43M), DAL (-$35M), PYPL (-$35M), AVTR (-$34M), ARGX (-$33M), ALNY (-$29M), BNTX (-$29M), Z (-$29M).
- Sold out of its positions in AGIO, AKBA, ALEC, ALXN, ASND, AVTR, BPMC, CLVS, CYRX, DAL. HTHT, IMMU, MGTA, MLCO, NKTR, PYPL, Principia Biopharma, Restorbio, TSM, TCDA, VNET.
- Artal Group was a net buyer of stock by $544M.
- Artal Group has $4.1B in assets under management (AUM), dropping by 15.25%.
Tip: Access up to 7 years of quarterly data
Positions held by Artal Group S.A. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artal Group
Companies in the Artal Group portfolio as of the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 13.9 | $572M | NEW | 2.1M | 277.84 | |
| Ww Intl (WW) | 6.8 | $280M | 15M | 18.87 | ||
| Beigene Sponsored Adr (BGNE) | 6.3 | $258M | +5% | 900k | 286.44 | |
| Goldman Sachs Call Option (GS) | 4.3 | $176M | +337% | 875k | 200.97 | |
| Acceleron Pharma (XLRN) | 3.8 | $158M | 1.4M | 112.53 | ||
| Alibaba Group Hldg Sponsored Ads (BABA) | 3.0 | $125M | +14% | 425k | 293.98 | |
| Biontech Se Sponsored Ads (BNTX) | 2.9 | $120M | -19% | 1.7M | 69.23 | |
| Alnylam Pharmaceuticals (ALNY) | 2.8 | $117M | -20% | 800k | 145.60 | |
| JPMorgan Chase & Co. Call Option (JPM) | 2.3 | $96M | -66% | 1.0M | 96.27 | |
| Generation Bio (GBIO) | 2.1 | $87M | 2.8M | 30.91 | ||
| Lexicon Pharmaceuticals Com New (LXRX) | 2.1 | $87M | 60M | 1.44 | ||
| Argenx Se Sponsored Adr (ARGX) | 2.1 | $85M | -27% | 324k | 262.52 | |
| Mirati Therapeutics (MRTX) | 2.0 | $83M | NEW | 500k | 166.05 | |
| GDS HLDGS Sponsored Ads (GDS) | 2.0 | $82M | -9% | 1.0M | 81.83 | |
Setup an alertArtal Group will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Allovir | 1.6 | $64M | NEW | 2.3M | 27.50 | |
| Fate Therapeutics (FATE) | 1.5 | $60M | -16% | 1.5M | 39.97 | |
| Amicus Therapeutics (FOLD) | 1.4 | $57M | -11% | 4.0M | 14.12 | |
| Ke Hldgs Sponsored Ads | 1.3 | $53M | NEW | 870k | 61.30 | |
| Igm Biosciences (IGMS) | 1.2 | $51M | NEW | 689k | 73.81 | |
| Bank of America Corporation Call Option (BAC) | 1.2 | $48M | +100% | 2.0M | 24.09 | |
| Black Diamond Therapeutics (BDTX) | 1.1 | $46M | 1.5M | 30.23 | ||
| Morphic Hldg (MORF) | 1.1 | $45M | 1.7M | 27.34 | ||
| Scholar Rock Hldg Corp (SRRK) | 1.1 | $44M | 2.5M | 17.69 | ||
| Abbvie Call Option (ABBV) | 1.1 | $44M | +100% | 500k | 87.59 | |
| Schrodinger (SDGR) | 1.0 | $43M | 897k | 47.51 | ||
| Tg Therapeutics (TGTX) | 1.0 | $40M | -14% | 1.5M | 26.76 | |
| Select Sector Spdr Tr Sbi Int-inds Call Option (XLI) | 0.9 | $39M | +11% | 500k | 76.98 | |
| I Mab Sponsored Ads (IMAB) | 0.8 | $34M | +123% | 725k | 47.03 | |
| Novagold Res Com New (NG) | 0.8 | $31M | 2.6M | 11.89 | ||
| Deciphera Pharmaceuticals (DCPH) | 0.7 | $31M | -7% | 600k | 51.30 | |
| Gossamer Bio (GOSS) | 0.7 | $29M | -11% | 2.4M | 12.41 | |
| Atara Biotherapeutics (ATRA) | 0.7 | $29M | -10% | 2.3M | 12.96 | |
| Albireo Pharma (ALBO) | 0.7 | $28M | +70% | 851k | 33.37 | |
| Turning Point Therapeutics I (TPTX) | 0.7 | $28M | -7% | 325k | 87.36 | |
| Uniqure Nv SHS (QURE) | 0.7 | $28M | -25% | 750k | 36.83 | |
| Agenus Com New (AGEN) | 0.7 | $28M | +142% | 6.9M | 4.00 | |
| Iteos Therapeutics | 0.7 | $27M | NEW | 1.1M | 24.67 | |
| Taysha Gene Therapies Com Shs | 0.6 | $26M | NEW | 1.1M | 22.40 | |
| Morgan Stanley Com New Call Option (MS) | 0.6 | $24M | NEW | 500k | 48.35 | |
| Apple Call Option (AAPL) | 0.6 | $23M | NEW | 200k | 115.81 | |
| Citigroup Com New Call Option (C) | 0.5 | $22M | -50% | 500k | 43.11 | |
| Trillium Therapeutics Com New (TRIL) | 0.5 | $21M | +57% | 1.5M | 14.21 | |
| Moderna (MRNA) | 0.5 | $21M | -40% | 300k | 70.75 | |
| Stoneco Com Cl A (STNE) | 0.5 | $21M | +37% | 400k | 52.89 | |
| Zillow Group Cl C Cap Stk (Z) | 0.5 | $20M | -58% | 200k | 101.59 | |
| Translate Bio (TBIO) | 0.5 | $19M | -12% | 1.4M | 13.61 | |
| Rubius Therapeutics (RUBY) | 0.5 | $19M | 3.8M | 5.01 | ||
| Mersana Therapeutics (MRSN) | 0.5 | $19M | +25% | 1.0M | 18.62 | |
| Adverum Biotechnologies (ADVM) | 0.5 | $19M | +100% | 1.8M | 10.30 | |
| Trip Com Group Ads (TCOM) | 0.4 | $18M | -5% | 570k | 31.14 | |
| Repare Therapeutics Ord (RPTX) | 0.4 | $18M | -5% | 570k | 30.77 | |
| Relay Therapeutics | 0.4 | $17M | NEW | 400k | 42.59 | |
| Kura Oncology (KURA) | 0.4 | $17M | -5% | 549k | 30.64 | |
| Danaher Corporation (DHR) | 0.4 | $16M | NEW | 75k | 215.33 | |
| Replimune Group (REPL) | 0.4 | $16M | -6% | 700k | 23.02 | |
| Fibrogen (FGEN) | 0.4 | $16M | -5% | 380k | 41.12 | |
| Bridgebio Pharma (BBIO) | 0.4 | $15M | -33% | 400k | 37.52 | |
| Bio-techne Corporation (TECH) | 0.4 | $15M | -7% | 60k | 247.73 | |
| Immunic (IMUX) | 0.4 | $15M | +33% | 800k | 18.57 | |
| General Motors Company Call Option (GM) | 0.4 | $15M | 500k | 29.59 | ||
| Aurinia Pharmaceuticals (AUPH) | 0.4 | $15M | +11% | 1.0M | 14.73 | |
| Ovid Therapeutics (OVID) | 0.3 | $14M | NEW | 2.5M | 5.74 | |
| Denali Therapeutics (DNLI) | 0.3 | $14M | -11% | 400k | 35.83 | |
| Harpoon Therapeutics (HARP) | 0.3 | $14M | -11% | 800k | 16.99 | |
| Sage Therapeutics (SAGE) | 0.3 | $14M | -5% | 222k | 61.12 | |
| Springworks Therapeutics (SWTX) | 0.3 | $14M | -5% | 285k | 47.67 | |
| Metacrine Ord | 0.3 | $13M | NEW | 1.3M | 10.21 | |
| Iovance Biotherapeutics (IOVA) | 0.3 | $13M | -20% | 400k | 32.92 | |
| Cardiff Oncology (CRDF) | 0.3 | $13M | NEW | 900k | 14.19 | |
| Epizyme (EPZM) | 0.3 | $12M | -65% | 1.0M | 11.93 | |
| BioMarin Pharmaceutical Call Option (BMRN) | 0.3 | $11M | NEW | 150k | 76.08 | |
| Selecta Biosciences (SELB) | 0.3 | $11M | +55% | 4.5M | 2.48 | |
| Cyclerion Therapeutics (CYCN) | 0.3 | $11M | 1.8M | 6.06 | ||
| Y Mabs Therapeutics (YMAB) | 0.3 | $11M | -5% | 285k | 38.39 | |
| Royalty Pharma Shs Class A (RPRX) | 0.3 | $11M | -66% | 250k | 42.07 | |
| Krystal Biotech (KRYS) | 0.2 | $10M | +18% | 238k | 43.05 | |
| Tcr2 Therapeutics Inc cs (TCRR) | 0.2 | $10M | +42% | 500k | 20.32 | |
| Esperion Therapeutics (ESPR) | 0.2 | $9.3M | NEW | 250k | 37.17 | |
| Stoke Therapeutics (STOK) | 0.2 | $9.1M | -5% | 271k | 33.49 | |
| Seres Therapeutics (MCRB) | 0.2 | $8.5M | NEW | 300k | 28.31 | |
| Kymera Therapeutics | 0.2 | $8.1M | NEW | 250k | 32.31 | |
| Applied Therapeutics (APLT) | 0.2 | $7.9M | NEW | 380k | 20.76 | |
| Dyne Therapeutics | 0.2 | $7.5M | NEW | 370k | 20.19 | |
| Aeglea Biotherapeutics (AGLE) | 0.2 | $7.4M | -5% | 1.0M | 7.09 | |
| Pmv Pharmaceuticals | 0.2 | $7.1M | NEW | 200k | 35.50 | |
| Bruker Corporation (BRKR) | 0.2 | $7.0M | -5% | 175k | 39.75 | |
| Spero Therapeutics (SPRO) | 0.2 | $6.7M | +10% | 600k | 11.16 | |
| Aravive (ARAV) | 0.1 | $6.2M | -4% | 1.3M | 4.70 | |
| American Airls Call Option (AAL) | 0.1 | $6.1M | -75% | 500k | 12.29 | |
| Regenxbio Inc equity us cm (RGNX) | 0.1 | $6.1M | -5% | 222k | 27.52 | |
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $5.7M | -5% | 1.2M | 4.79 | |
| Hookipa Pharma Inc equity (HOOK) | 0.1 | $5.7M | 600k | 9.47 | ||
| Leap Therapeutics (LPTX) | 0.1 | $5.6M | -5% | 2.8M | 1.98 | |
| Kaleido Biosciences Ord (KLDO) | 0.1 | $5.5M | 501k | 11.07 | ||
| Alpine Immune Sciences (ALPN) | 0.1 | $5.2M | NEW | 593k | 8.79 | |
| Aptinyx (APTX) | 0.1 | $5.1M | -5% | 1.5M | 3.38 | |
| Vaxart Com New (VXRT) | 0.1 | $5.0M | +275% | 750k | 6.65 | |
| Ac Immune Sa SHS (ACIU) | 0.1 | $4.9M | 1.0M | 4.88 | ||
| Adaptive Biotechnologies Cor (ADPT) | 0.1 | $4.9M | -46% | 100k | 48.63 | |
| Accelr8 Technology (AXDX) | 0.1 | $4.6M | -27% | 428k | 10.66 | |
| Syros Pharmaceuticals (SYRS) | 0.1 | $4.1M | -5% | 466k | 8.84 | |
| 111 Ads (YI) | 0.1 | $4.0M | 650k | 6.20 | ||
| Avidity Biosciences Ord (RNA) | 0.1 | $4.0M | -18% | 143k | 28.15 | |
| Intellia Therapeutics (NTLA) | 0.1 | $3.8M | -20% | 190k | 19.88 | |
| Alx Oncology Hldgs | 0.1 | $3.8M | NEW | 100k | 37.74 | |
| Occidental Petroleum Corporation (OXY) | 0.1 | $3.8M | NEW | 375k | 10.01 | |
| Oric Pharmaceuticals (ORIC) | 0.1 | $3.6M | -5% | 143k | 25.01 | |
| Prothena Corp SHS (PRTA) | 0.1 | $3.5M | -5% | 352k | 9.99 | |
| Solid Biosciences (SLDB) | 0.1 | $3.5M | -5% | 1.7M | 2.03 | |
| Autolus Therapeutics Sponsored Ads (AUTL) | 0.1 | $3.3M | -28% | 285k | 11.64 | |
| Axcella Health Inc equity (AXLA) | 0.1 | $3.3M | -20% | 713k | 4.62 | |
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $3.1M | -30% | 95k | 32.99 | |
| Prevail Therapeutics Ord (PRVL) | 0.1 | $3.1M | -18% | 303k | 10.18 | |
| Merus N V (MRUS) | 0.1 | $3.0M | -34% | 250k | 12.00 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $2.9M | -5% | 87k | 32.69 | |
| Protagonist Therapeutics (PTGX) | 0.1 | $2.6M | -5% | 133k | 19.55 | |
| Evelo Biosciences (EVLO) | 0.1 | $2.5M | -28% | 475k | 5.27 | |
| Minerva Neurosciences (NERV) | 0.1 | $2.4M | -5% | 760k | 3.18 | |
| Mei Pharma Com New (MEIP) | 0.1 | $2.4M | +6% | 760k | 3.12 | |
| Aduro Biotech | 0.1 | $2.2M | -5% | 903k | 2.43 | |
| Pandion Therapeutics | 0.0 | $1.7M | NEW | 145k | 11.46 | |
| Curis Com New (CRIS) | 0.0 | $1.6M | -4% | 1.4M | 1.17 | |
| Chiasma (CHMA) | 0.0 | $1.6M | NEW | 380k | 4.30 | |
| Adicet Bio | 0.0 | $1.5M | NEW | 129k | 11.89 | |
| Select Sector Spdr Tr Energy Call Option (XLE) | 0.0 | $1.5M | 50k | 29.96 | ||
| Orchard Therapeutics Ads (ORTX) | 0.0 | $1.4M | -5% | 352k | 4.11 | |
| Cytomx Therapeutics (CTMX) | 0.0 | $1.2M | -5% | 179k | 6.65 | |
| Bellus Health Com New (BLU) | 0.0 | $1.1M | +230% | 475k | 2.27 | |
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.0 | $994k | 111k | 8.99 | ||
| Rigel Pharmaceuticals Com New (RIGL) | 0.0 | $771k | -5% | 321k | 2.40 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.0 | $640k | -5% | 225k | 2.85 | |
| Passage Bio (PASG) | 0.0 | $205k | -93% | 16k | 13.10 | |
| Ideaya Biosciences (IDYA) | 0.0 | $0 | -99% | 8.00 | 0.00 | |
Past Filings by Artal Group
SEC 13F filings are viewable for Artal Group going back to 2012
- Artal Group 2020 Q3 filed Nov. 13, 2020
- Artal Group 2020 Q2 filed Aug. 14, 2020
- Artal Group 2020 Q1 filed May 14, 2020
- Artal Group 2019 Q4 filed Feb. 13, 2020
- Artal Group 2019 Q3 filed Nov. 14, 2019
- Artal Group 2019 Q2 filed Aug. 9, 2019
- Artal Group 2019 Q1 filed May 10, 2019
- Artal Group 2018 Q4 filed Feb. 11, 2019
- Artal Group 2018 Q3 filed Nov. 9, 2018
- Artal Group 2018 Q2 filed Aug. 10, 2018
- Artal Group 2018 Q1 filed May 10, 2018
- Artal Group 2017 Q4 filed Feb. 9, 2018
- Artal Group 2017 Q3 filed Nov. 8, 2017
- Artal Group 2017 Q2 filed Aug. 11, 2017
- Artal Group 2017 Q1 filed May 15, 2017
- Artal Group 2016 Q4 filed Feb. 14, 2017